Developer docs
API playgroundTry for free, no card

Search company profiles

Delcath Systems

Full company profile

uuid00036w3

Namestring
Delcath Systems
Legal namestring
Delcath Systems, Inc.
Websiteurl
delcath.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Delcath Systems, Inc. is a commercial-stage interventional oncology company headquartered in Queens, New York, focused on treating primary and metastatic liver cancers. The company's core technology is the Hepatic Delivery System (HDS), which enables Percutaneous Hepatic Perfusion (PHP): a minimally invasive procedure that temporarily isolates the liver from systemic circulation, delivers a 30-minute high-dose infusion of melphalan chemotherapy directly to the liver, and filters excess drug from the blood through proprietary filters before returning it to the patient. The product is sold as HEPZATO KIT in the United States following FDA approval on August 14, 2023 for adult patients with metastatic uveal melanoma with liver dominant disease, and as CHEMOSAT Hepatic Delivery System for Melphalan in Europe.

The business model is a direct enterprise field-sales motion into major cancer centers and academic hospitals, with each procedure consuming a HEPZATO KIT / CHEMOSAT single-use drug-device combination. In the United States, HEPZATO KIT generated approximately $78.8M in 2025 full-year sales and $23.3M in Q1 2026, while European CHEMOSAT sales contributed $1.7M in Q1 2026. The company is expanding its commercial footprint toward 40 active US treatment centers by year-end 2026 and is conducting clinical trials in metastatic breast and colorectal cancer with liver dominant disease to expand indications beyond uveal melanoma. Revenue grew from $37.2M in 2024 to $85.2M in 2025 (more than 40% volume growth), the company achieved first-time annual net income of $2.7M, and exited 2025 with $91M in cash and no debt.

Beyond the current indication, the company is pursuing label expansion through the CHOPIN Phase 2 trial (results published in The Lancet Oncology showing 54.7% one-year progression-free survival in combination versus 15.8% for PHP alone) and additional investigator-initiated studies presented at ASCO 2026 combining HEPZATO with tebentafusp and with nivolumab/relatlimab. Strategic and clinical partners include Cleveland Clinic, Moffitt, City of Hope, UCLA, and Leiden University Medical Center, with capital backing from Vivo Capital and Rosalind Advisors.

Short descriptiontext

Delcath Systems is a commercial-stage interventional oncology company that develops and sells HEPZATO KIT in the US and CHEMOSAT in Europe, proprietary Hepatic Delivery Systems for Percutaneous Hepatic Perfusion that deliver high-dose melphalan directly to the liver to treat metastatic liver cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interventional oncology, hepatic chemotherapy delivery, percutaneous hepatic perfusion, liver cancer treatment, melphalan delivery system
Industry3 codes
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAK
Gastrointestinal Oncology
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Interventional Oncology Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1HEPZATO KIT Sales (US)
TypeHardware Sales
Description

Revenue from sales of HEPZATO KIT in the United States following FDA approval in August 2023. HEPZATO KIT generated $23.3 million in Q1 2026 US sales and $78.8 million for full year 2025.

stocktitan.net
2CHEMOSAT Sales (Europe)
TypeHardware Sales
Description

Revenue from sales of CHEMOSAT Hepatic Delivery System in Europe. CHEMOSAT generated $1.7 million in Q1 2026 European sales.

stocktitan.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1HEPZATO KIT™
Description

FDA-approved treatment product for metastatic uveal melanoma in the United States. Melphalan for Injection/Hepatic Delivery System (HDS).

delcath.com
+1 more record
Core offering1 text field

Delcath Systems is a commercial-stage interventional oncology company that develops, manufactures, and sells the Hepatic Delivery System (HDS) used for Percutaneous Hepatic Perfusion (PHP). Its two commercial products are HEPZATO KIT (US, FDA-approved August 2023) and CHEMOSAT (Europe), which deliver high-dose melphalan chemotherapy directly to the liver while proprietary filters remove excess drug from the blood before returning it to systemic circulation. The primary indication is adult patients with metastatic uveal melanoma with liver-dominant disease, with ongoing trials for metastatic breast and colorectal cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1-year progression-free survival of 54.7% vs 15.8% (combination therapy vs PHP alone) in CHOPIN Phase 2 trial
+3 more records
Product overview1 text field

Delcath Systems is a commercial-stage interventional oncology company with two core product platforms: HEPZATO KIT™ (US) and CHEMOSAT® (Europe), both consisting of a Hepatic Delivery System for percutaneous hepatic perfusion (PHP) that delivers high-dose melphalan chemotherapy directly to the liver. The systems include proprietary filtration technology to remove excess chemotherapy from the blood before returning it to systemic circulation, reducing drug-related side effects. The company is currently conducting clinical trials to expand the indication of these products for metastatic breast cancer and colorectal cancer with liver dominant disease.

Product and service2 records
1HEPZATO KIT (melphalan) for Injection/Hepatic Delivery System (HDS)
CategoryInterventional Oncology Drug-Device Combination Product
Description

FDA-approved percutaneous hepatic perfusion system that delivers high-dose melphalan chemotherapy directly to the liver while filtering excess drug from the blood before returning it to systemic circulation. Indicated for adult patients with metastatic uveal melanoma with liver-dominant disease in the United States.

2CHEMOSAT Hepatic Delivery System for Melphalan
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Clinical trial site for metastatic breast cancer study (NCT06875128), evaluating HEPZATO in combination with approved cancer treatments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Clinical trial site for metastatic breast cancer study (NCT06875128), evaluating HEPZATO in combination with approved cancer treatments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Clinical trial site for metastatic colorectal cancer study (NCT06607458), one of the leading US cancer research and treatment organizations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Clinical trial site for metastatic colorectal cancer study (NCT06607458), conducting research on liver-directed therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Led the CHOPIN Phase 2 clinical trial, published results in The Lancet Oncology demonstrating efficacy of HEPZATO combined with immunotherapy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1HistoSonics
TypeEmerging player
Description

HistoSonics is developing histotripsy, a non-invasive, non-thermal focused ultrasound platform for destroying liver tumors. It represents an emerging non-thermal alternative to Delcath's PHP for liver-directed tumor ablation in metastatic disease.

TypeDirect peer
Description

Sirtex manufactures SIR-Spheres Y-90 resin microspheres for selective internal radiation therapy (SIRT) in liver-dominant metastatic disease — a directly competing liver-directed interventional oncology modality targeting the same patient population Delcath is pursuing in colorectal and breast cancer indications.

TypeBroad incumbent
Description

Medtronic operates a broad interventional portfolio including embolization and ablation technologies (e.g., Emprint, OptiSphere) that overlap with Delcath's liver-directed interventional oncology positioning, though Medtronic serves a much wider procedural footprint.

TypeBroad incumbent
Description

Inari Medical is a commercial-stage interventional company (acquired by Stryker) with catheter-based therapies for venous thromboembolism and emerging peripheral interventions. It is comparable as a catheter-based interventional oncology/vascular peer in commercial motion and procedural complexity, though its primary indication set differs.

TypeEmerging player
Description

Replimune is developing oncolytic immunotherapy approaches (RP1/RP2/RP3) for melanoma and other solid tumors. As immunotherapy-based options expand in metastatic uveal melanoma, Replimune represents an emerging combination or alternative therapy to Delcath's PHP approach.

TypeDirect peer
Description

AngioDynamics offers NanoKnife irreversible electroporation and other interventional oncology technologies for liver and other solid tumors. It competes directly with Delcath in the percutaneous, minimally invasive liver-directed interventional oncology segment.

TypeBroad incumbent
Description

Varian, now part of Siemens Healthineers, is a global leader in radiation oncology including stereotactic body radiation therapy (SBRT) for liver metastases. It serves the same oncology patient population with an overlapping liver-directed treatment approach but at much greater scale and with broader indications.

TypeDirect peer
Description

Immunocore developed tebentafusp (Kimmtrak), the first FDA-approved therapy for metastatic uveal melanoma and current standard-of-care for HLA-A*02:01-positive patients. It competes head-to-head with HEPZATO in the same indication and is the primary competitive threat to Delcath's anchor franchise.

TypeDirect peer
Description

Boston Scientific acquired BTG's TheraSphere Y-90 glass microsphere franchise, a benchmark interventional oncology liver-directed therapy. CCO Kevin Muir previously led TheraSphere US sales at BTG and Chairman John Sylvester was CCO of BTG plc, underscoring the direct overlap with Delcath's PHP-based approach.

TypeBroad incumbent
Description

Penumbra is an interventional company with growing oncology and embolization franchises adjacent to hepatic tumor therapy. While not a direct PHP competitor, it shares the minimally invasive interventional oncology commercial channel and customer base of cancer centers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delcath Systems

Interventional Oncology Medical Devicesdelcath.com

Delcath Systems is a commercial-stage interventional oncology company that develops and sells HEPZATO KIT in the US and CHEMOSAT in Europe, proprietary Hepatic Delivery Systems for Percutaneous Hepatic Perfusion that deliver high-dose melphalan directly to the liver to treat metastatic liver cancers.

What Delcath Systems does

Delcath Systems, Inc. is a commercial-stage interventional oncology company headquartered in Queens, New York, focused on treating primary and metastatic liver cancers. The company's core technology is the Hepatic Delivery System (HDS), which enables Percutaneous Hepatic Perfusion (PHP): a minimally invasive procedure that temporarily isolates the liver from systemic circulation, delivers a 30-minute high-dose infusion of melphalan chemotherapy directly to the liver, and filters excess drug from the blood through proprietary filters before returning it to the patient. The product is sold as HEPZATO KIT in the United States following FDA approval on August 14, 2023 for adult patients with metastatic uveal melanoma with liver dominant disease, and as CHEMOSAT Hepatic Delivery System for Melphalan in Europe.

The business model is a direct enterprise field-sales motion into major cancer centers and academic hospitals, with each procedure consuming a HEPZATO KIT / CHEMOSAT single-use drug-device combination. In the United States, HEPZATO KIT generated approximately $78.8M in 2025 full-year sales and $23.3M in Q1 2026, while European CHEMOSAT sales contributed $1.7M in Q1 2026. The company is expanding its commercial footprint toward 40 active US treatment centers by year-end 2026 and is conducting clinical trials in metastatic breast and colorectal cancer with liver dominant disease to expand indications beyond uveal melanoma. Revenue grew from $37.2M in 2024 to $85.2M in 2025 (more than 40% volume growth), the company achieved first-time annual net income of $2.7M, and exited 2025 with $91M in cash and no debt.

Beyond the current indication, the company is pursuing label expansion through the CHOPIN Phase 2 trial (results published in The Lancet Oncology showing 54.7% one-year progression-free survival in combination versus 15.8% for PHP alone) and additional investigator-initiated studies presented at ASCO 2026 combining HEPZATO with tebentafusp and with nivolumab/relatlimab. Strategic and clinical partners include Cleveland Clinic, Moffitt, City of Hope, UCLA, and Leiden University Medical Center, with capital backing from Vivo Capital and Rosalind Advisors.

Delcath Systems firmographics

Firmographics
Name
Delcath Systems
Legal name
Delcath Systems, Inc.
Website
https://delcath.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
101–250 employees
Short description
Delcath Systems is a commercial-stage interventional oncology company that develops and sells HEPZATO KIT in the US and CHEMOSAT in Europe, proprietary Hepatic Delivery Systems for Percutaneous Hepatic Perfusion that deliver high-dose melphalan directly to the liver to treat metastatic liver cancers.
Ownership category
akta.pro rank

Delcath Systems industry classification

Industry
Product category
Interventional Oncology Medical Devices
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAK
Gastrointestinal Oncology

Keywords

  • Interventional oncology
  • Hepatic chemotherapy delivery
  • Percutaneous hepatic perfusion
  • Liver cancer treatment
  • Melphalan delivery system

Where Delcath Systems is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Delcath Systems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. HEPZATO KIT Sales (US): Revenue from sales of HEPZATO KIT in the United States following FDA approval in August 2023. HEPZATO KIT generated $23.3 million in Q1 2026 US sales and $78.8 million for full year 2025.
  2. CHEMOSAT Sales (Europe): Revenue from sales of CHEMOSAT Hepatic Delivery System in Europe. CHEMOSAT generated $1.7 million in Q1 2026 European sales.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Delcath Systems product offering

Product offering

Core offering

Delcath Systems is a commercial-stage interventional oncology company that develops, manufactures, and sells the Hepatic Delivery System (HDS) used for Percutaneous Hepatic Perfusion (PHP). Its two commercial products are HEPZATO KIT (US, FDA-approved August 2023) and CHEMOSAT (Europe), which deliver high-dose melphalan chemotherapy directly to the liver while proprietary filters remove excess drug from the blood before returning it to systemic circulation. The primary indication is adult patients with metastatic uveal melanoma with liver-dominant disease, with ongoing trials for metastatic breast and colorectal cancer.

Product overview

Delcath Systems is a commercial-stage interventional oncology company with two core product platforms: HEPZATO KIT™ (US) and CHEMOSAT® (Europe), both consisting of a Hepatic Delivery System for percutaneous hepatic perfusion (PHP) that delivers high-dose melphalan chemotherapy directly to the liver. The systems include proprietary filtration technology to remove excess chemotherapy from the blood before returning it to systemic circulation, reducing drug-related side effects. The company is currently conducting clinical trials to expand the indication of these products for metastatic breast cancer and colorectal cancer with liver dominant disease.

Differentiator

Problem solved

Functional benefit

Brands

  • HEPZATO KIT™: FDA-approved treatment product for metastatic uveal melanoma in the United States. Melphalan for Injection/Hepatic Delivery System (HDS).
  • CHEMOSAT®

Products and services

  • HEPZATO KIT (melphalan) for Injection/Hepatic Delivery System (HDS) FDA-approved percutaneous hepatic perfusion system that delivers high-dose melphalan chemotherapy directly to the liver while filtering excess drug from the blood before returning it to systemic circulation. Indicated for adult patients with metastatic uveal melanoma with liver-dominant disease in the United States.
  • CHEMOSAT Hepatic Delivery System for Melphalan

Quantifiable outcome

  • 1-year progression-free survival of 54.7% vs 15.8% (combination therapy vs PHP alone) in CHOPIN Phase 2 trial
  • +3 more outcomes

Companies that use Delcath Systems

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Delcath Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Delcath Systems partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Cleveland ClinicminorStrategic or Co-development Partner · 1 January 2025Clinical trial site for metastatic breast cancer study (NCT06875128), evaluating HEPZATO in combination with approved cancer treatments.
  • Moffitt Cancer CenterminorStrategic or Co-development Partner · 1 January 2025Clinical trial site for metastatic breast cancer study (NCT06875128), evaluating HEPZATO in combination with approved cancer treatments.
  • City of HopeminorStrategic or Co-development Partner · 1 January 2025Clinical trial site for metastatic colorectal cancer study (NCT06607458), one of the leading US cancer research and treatment organizations.
  • UCLA (University of California, Los Angeles)minorStrategic or Co-development Partner · 1 January 2025Clinical trial site for metastatic colorectal cancer study (NCT06607458), conducting research on liver-directed therapies.
  • Leiden University Medical CentercoreStrategic or Co-development Partner · 1 January 2025Led the CHOPIN Phase 2 clinical trial, published results in The Lancet Oncology demonstrating efficacy of HEPZATO combined with immunotherapy.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Delcath Systems competitors and assessment

Company assessment

Emerging players

  • HistoSonics: HistoSonics is developing histotripsy, a non-invasive, non-thermal focused ultrasound platform for destroying liver tumors. It represents an emerging non-thermal alternative to Delcath's PHP for liver-directed tumor ablation in metastatic disease.
  • Replimune: Replimune is developing oncolytic immunotherapy approaches (RP1/RP2/RP3) for melanoma and other solid tumors. As immunotherapy-based options expand in metastatic uveal melanoma, Replimune represents an emerging combination or alternative therapy to Delcath's PHP approach.

Direct peers

  • Sirtex Medical: Sirtex manufactures SIR-Spheres Y-90 resin microspheres for selective internal radiation therapy (SIRT) in liver-dominant metastatic disease — a directly competing liver-directed interventional oncology modality targeting the same patient population Delcath is pursuing in colorectal and breast cancer indications.
  • AngioDynamics: AngioDynamics offers NanoKnife irreversible electroporation and other interventional oncology technologies for liver and other solid tumors. It competes directly with Delcath in the percutaneous, minimally invasive liver-directed interventional oncology segment.
  • Immunocore: Immunocore developed tebentafusp (Kimmtrak), the first FDA-approved therapy for metastatic uveal melanoma and current standard-of-care for HLA-A*02:01-positive patients. It competes head-to-head with HEPZATO in the same indication and is the primary competitive threat to Delcath's anchor franchise.
  • Boston Scientific (TheraSphere): Boston Scientific acquired BTG's TheraSphere Y-90 glass microsphere franchise, a benchmark interventional oncology liver-directed therapy. CCO Kevin Muir previously led TheraSphere US sales at BTG and Chairman John Sylvester was CCO of BTG plc, underscoring the direct overlap with Delcath's PHP-based approach.

Broad incumbents

  • Medtronic: Medtronic operates a broad interventional portfolio including embolization and ablation technologies (e.g., Emprint, OptiSphere) that overlap with Delcath's liver-directed interventional oncology positioning, though Medtronic serves a much wider procedural footprint.
  • Inari Medical: Inari Medical is a commercial-stage interventional company (acquired by Stryker) with catheter-based therapies for venous thromboembolism and emerging peripheral interventions. It is comparable as a catheter-based interventional oncology/vascular peer in commercial motion and procedural complexity, though its primary indication set differs.
  • Varian Medical Systems (Siemens Healthineers): Varian, now part of Siemens Healthineers, is a global leader in radiation oncology including stereotactic body radiation therapy (SBRT) for liver metastases. It serves the same oncology patient population with an overlapping liver-directed treatment approach but at much greater scale and with broader indications.
  • Penumbra: Penumbra is an interventional company with growing oncology and embolization franchises adjacent to hepatic tumor therapy. While not a direct PHP competitor, it shares the minimally invasive interventional oncology commercial channel and customer base of cancer centers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Delcath Systems social profiles

Digital presence

Delcath Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delcath Systems leadership team

Management profile

Number of profiles

Profiles12 records

Delcath Systems funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delcath Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delcath Systems

What does Delcath Systems do?

Delcath Systems is a commercial-stage interventional oncology company that develops, manufactures, and sells the Hepatic Delivery System (HDS) used for Percutaneous Hepatic Perfusion (PHP). Its two commercial products are HEPZATO KIT (US, FDA-approved August 2023) and CHEMOSAT (Europe), which deliver high-dose melphalan chemotherapy directly to the liver while proprietary filters remove excess drug from the blood before returning it to systemic circulation. The primary indication is adult patients with metastatic uveal melanoma with liver-dominant disease, with ongoing trials for metastatic breast and colorectal cancer.

Is Delcath Systems a public or private company?

Delcath Systems is a public company. It is classified as public and is currently operating.

When was Delcath Systems founded?

Delcath Systems was founded in 1987. It employs 101 to 250 people.

Where is Delcath Systems based?

Delcath Systems is headquartered in New York, United States, in the North America region.

How does Delcath Systems make money?

Two revenue lines are on record. HEPZATO KIT Sales (US) is the primary driver. The others are CHEMOSAT Sales (Europe).

Who are Delcath Systems's main competitors?

Emerging players on record are HistoSonics and Replimune. Direct peers are Sirtex Medical, AngioDynamics, Immunocore and Boston Scientific (TheraSphere). Broad incumbents are Medtronic, Inari Medical, Varian Medical Systems (Siemens Healthineers) and Penumbra.

Does Delcath Systems have an API?

No public API is recorded for Delcath Systems.

What industry is Delcath Systems in?

Delcath Systems's product category is Interventional Oncology Medical Devices. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems granted 21,250 restricted stock units to three individuals on November 2, 2026, as inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs vest one-third on the first anniversary and two-thirds over the following two years, subject to continued employment.TradingViewDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems granted 21,250 restricted stock units to three individuals on November 2, 2026, as material inducements under Nasdaq Listing Rule 5635(c)(4). The RSUs vest one-third on the first anniversary and two-thirds over the following two years, subject to continued employment.Investing.comDelcath Systems stock rating reiterated at Buy by BTIGBTIG reiterated a Buy rating and $25 price target on Delcath Systems, which trades at $21.77. The company reported Q3 2026 earnings of 17 cents per share and $35.1 million revenue, beating estimates. BTIG raised its price target from $21 to $25.American Banking and Market NewsHC Wainwright Forecasts Strong Price Appreciation for Delcath Systems (NASDAQ:DCTH) StockHC Wainwright raised its price target on Delcath Systems from $32 to $36, keeping a buy rating. The stock opened at $21.77, and Delcath reported Q2 EPS of $0.17, beating estimates, with revenue of $35.1 million. Analysts project EPS of $0.11 for Q2 2027 and $0.68 for FY2028.Simply Wall StWith EPS Growth And More, Delcath Systems (NASDAQ:DCTH) Makes An Interesting CaseDelcath Systems reported EPS growth from $0.035 to $0.19 in one year, with revenue rising 38% to $110m. Insiders bought $189k of stock, including $100k by CEO Gerard Michel, holding over 7.1% of shares. The company may be at an inflection point if EBIT margins stabilize.Defense WorldHC Wainwright Issues Positive Forecast for Delcath Systems (NASDAQ:DCTH) Stock PriceH.C. Wainwright raised Delcath Systems' price target to $36 from $32, maintaining a Buy rating. The company reported Q3 2026 EPS of $0.17, beating estimates, and revenue of $35.1 million, above the $25.99 million consensus. It forecast 2026 revenue of $115–117 million and targets 36 treatment centers by year-end.MarketWatchDelcath Systems Hits 52-Week High on Earnings, GuidanceDelcath Systems shares rose to a 52-week high after the company reported a Q3 profit of 17 cents per share on $35.1 million in sales, beating analyst expectations. It also raised its full-year revenue guidance to $115-117 million, up from $104-108 million.Seeking AlphaDelcath outlines $115M-$117M 2026 revenue guidance while targeting at least 36 active centers by year-end (NASDAQ:DCTH)Delcath Systems reported Q3 2025 revenue of $35.1 million, up 71% year-over-year, and guided 2026 revenue to $115-117 million. The company also targets at least 36 active centers by year-end.ChartmillDelcath Systems (NASDAQ:DCTH) Stock Jumps Premarket on Strong Q3 2026 Earnings Beat and Above-Consensus GuidanceDelcath Systems reported Q3 2026 revenue of $35.1 million, beating the $26.5 million consensus, and diluted EPS of $0.17 versus an expected loss of $0.085. The company guided full-year 2026 revenue to $115–117 million, above the $108.6 million consensus, and the stock rose roughly 20.6% in premarket trading.BenzingaDelcath Systems Q3 2026 Earnings Call Transcript - Delcath Systems (NASDAQ:DCTH)Delcath Systems reported record Q3 2026 revenue of $35.1 million, up 71% year-over-year, driven by HEPZATO KIT adoption and new treatment centers. The company raised its 2026 full-year revenue guidance to $115-117 million and expects at least 36 active centers by year-end.